Pulmonx (LUNG) Liabilities and Shareholders Equity (2019 - 2025)

Pulmonx (LUNG) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $129.3 million in Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity fell 20.61% year-over-year to $129.3 million in Q4 2025; TTM through Dec 2025 was $565.5 million, a 15.28% decrease from a year earlier, with the FY2025 full-year figure at $129.3 million, down 20.61% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $129.3 million, down from $138.3 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for LUNG reached as high as $255.3 million in Q1 2021 and fell as low as $129.3 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $190.4 million across 5 years, with a median of $189.1 million in 2023.
• Across the five-year window, Liabilities and Shareholders Equity surged 246.44% in 2021 and retreated 20.61% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $235.2 million in 2021, then retreated by 17.65% to $193.7 million in 2022, then dropped by 8.21% to $177.8 million in 2023, then fell by 8.4% to $162.8 million in 2024, then slipped by 20.61% to $129.3 million in 2025.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $129.3 million in Q4 2025, $138.3 million in Q3 2025, and $147.2 million in Q2 2025.